Dr Peter Smith
Executive Director

Dr Peter Smith has over 30 years of experience in the pharmaceutical and biotech industry, with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies.

He is currently CEO of private biotechnology company Myrio Therapeutics which is developing a novel antibody platform able to rapidly identify TCR-like antibodies. Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD.

Prior to moving to Australia, Peter co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ IPOs, fundraisings, and M&A.

His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. In addition to serving as a Director of Race Oncology, he is also currently a Director of Myrio Therapeutics, MycRx Inc., Hula Therapeutics Inc. and Amala Therapeutics.

To view Dr Smith’s LinkedIn profile, please click here.